Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
ESMO Congress 2026 · Barcelona, Spain
5 shown of 2,595 total abstracts
  1. Abstract LBA4000LBA2026-09-03 · 16:30 CT · S406
    Quality of life outcomes with Opdivo in patients with RCC
    J. Cortes, A. Spira, S. Antonia, et al. · Chinese University of Hong Kong
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  2. Abstract LBA4001LBA2026-09-02 · 21:15 CT · Arie Crown Theater
    Biomarker subgroup analysis of Opdivo in RCC (the CheckMate-352 study)
    A. Spira, E. Winer, L. Paz-Ares, et al. · Johns Hopkins Kimmel Cancer Center
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  3. Abstract LBA4002LBA2026-09-04 · 13:30 CT · S406
    Long-term follow-up of Keytruda maintenance for RCC: KEYNOTE-22
    P. Schmid, C. Saura, S. Tolaney, et al. · Karolinska Institute
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  4. Abstract LBA4003LBA2026-09-04 · 16:30 CT · E450
    Opdivo plus chemotherapy in previously untreated RCC: updated analysis from CheckMate-186
    M.C. Garassino, L. Paz-Ares, G. Curigliano · MD Anderson Cancer Center
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
  5. Abstract LBA4004LBA2026-09-04 · 16:30 CT · Hall B1
    CheckMate-958: Opdivo (nivolumab) 1L in RCC
    C. Saura, H. Borghaei · Vall d'Hebron Institute of Oncology
    Plenary SessionGenitourinary Cancer—Kidney/Bladder📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.